Sacramento Municipal Utility District, California; Retail Electric Apr 09

  • ID: 1887286
  • April 2009
  • Region: California
  • Standard & Poors
1 of 3


  • Sacramento Mun Util Dist
  • MORE

Standard & Poor's Ratings Services raised its rating and underlying rating (SPUR) to 'A+' from 'A' on Sacramento Municipal Utility District (SMUD), Calif.'s outstanding senior-lien revenue bonds, and raised its SPUR to 'A' from 'A-' on the district's outstanding subordinate-lien revenue bonds. In addition, Standard & Poor's assigned its 'A+' rating to SMUD's $200 million series 2009V senior-lien electric revenue bonds. The raised ratings reflect our view of the district's continued strong and stable financial performance, its demonstrated willingness and ability to adjust rates to recover costs and maintain strong margins, its favorable resource portfolio, and its significant rate flexibility. The 'A+' senior-lien rating and SPUR additionally reflect our opinion of: The district's sound business strategy, which includes a focus...

Companies mentioned in this report are:
- Sacramento Mun Util Dist

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Sacramento Mun Util Dist

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.